METHOD OF TREATING PATIENTS WITH REFRACTORY AND RECURRENT CLINICAL COURSE OF HODGKIN'S LYMPHOMA Russian patent published in 2013 - IPC A61M1/36 A61K38/20 A61K38/21 A61P35/02 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to oncology and hematology, and may be used in treating the patients with refractory and recurrent clinical course of Hodgkin's lymphoma. For this purpose, 24 hours before the leucopheresis procedure, a granulocyte colony-stimulating factor is administered to the patient. That is followed by the leucopheresis procedure with using MCS "Haemonetics" blood separator, and the prepared leukapack is divided on 4 portions. The leukapack portions are collected in sterile containers and incubated for 180 minutes at temperature 37°C: portions 1 and 3 with recombinant interleukin-2 5 thousand IU/ml, portions 2 and 4 with interferon-α-2b 10 thousand IU/ml. That is followed by the intravenous, drop-by-drop reinfusions of the leukapack before a course of the polychemotherapy: portions 1 and 2 on the day of the leucopheresis procedure, portions 3 and 4 of the laukapack are kept in a fridge at temperature 0 to 8°C for 24 hours and then incubated with immune preparations in the specified mode and administered to the patient. After the course of the polychemotherapy has been completed, the leucopheresis procedure is conducted again. The above therapy is prescribed for cycles 4 and 6 of the polychemotherapy used for refractory Hodgkin lymphoma and for cycles 2 and 4 cycles of the polychemotherapy used for recurrent Hodgkin's lymphoma, regardless of a response to therapy.

EFFECT: method enables the effective therapy of the given pathology ensured by activation of the proper anti-tumour response.

2 ex